Faron Pharma News Today

Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer. The Turku, Finland-based clinical-stage...

Faron Pharma’s latest results from the BEXMAB trial in aggressive myeloid leukaemias (a rare blood cancer) showed more promising results, according to...

One of the weeks biggest casualties was Inland Homes , where forecast losses are now expected to be in the range of £90million, up from £37million.

Stop watching that documentary on slow-drying paint and check out the London stock market instead

Stop watching that documentary on slow-drying paint and check out the London stock market instead

The latest news on the science of Biotechnology, from the best sources of Biotechnology news. Get the latest Biotechnology news now.

Introduction This interim management statement covers the first quarter of the 2020/21 financial year, 1 October 2020 to 31 December 2020. Investment performance measures contained in this report are calculated on a pence per share basis and include realised and unrealised gains and losses. Investment report The quarter started with three areas of significant concern: a contested US election result; a no deal departure from the European Union; and a winter resurgence of CV19 pandemic.  The eve...